Morten Henneveld named interim CEO of Atlas Antibodies
Atlas Antibodies CEO Dan Pitulia has stepped down from his position. Morten Henneveld, formerly of OssDsign, has been appointed interim CEO effective November 1, 2026.
The board of Atlas Antibodies and CEO Dan Pitulia have reached a mutual agreement for Pitulia to depart from the company. The leadership transition was formalized on November 1, 2026.
Morten Henneveld has assumed the role of interim CEO. Henneveld most recently served as CEO of OssDsign and holds a background in the medical technology and life sciences sectors, with previous tenures at GN Group, Zimmer Biomet, and Coloplast.
The board noted that Henneveld’s experience in navigating strategic organizational changes will be a priority for the firm moving forward. No timeline has been provided regarding the appointment of a permanent successor.